Oxford Immunotec Global PLC Ordinary Shares
OXFD
OXFD was delisted on the 5th of March, 2021.
65 hedge funds and large institutions have $225M invested in Oxford Immunotec Global PLC Ordinary Shares in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 7 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 23
4% less funds holding
Funds holding: 68 → 65 (-3)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
44% less capital invested
Capital invested by funds: $404M → $225M (-$180M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
+$8.75M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$6.68M |
| 3 |
GPGA
Grandeur Peak Global Advisors
Salt Lake City,
Utah
|
+$4.46M |
| 4 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$2.41M |
| 5 |
DM
Deerfield Management
New York
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$15.6M |
| 2 |
FA
Friess Associates
Greenville,
Delaware
|
-$6.29M |
| 3 |
Man Group
London,
United Kingdom
|
-$4.74M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.58M |
| 5 |
EP
Eversept Partners
New York
|
-$2.48M |
OXFD Hedge Fund Activity: Q1 2020 in Review
65 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) for Q1 2020, worth a combined $225M — down 44% from $404M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of OXFD and 5 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 30 added.
The largest buyer was Senvest Management, adding an estimated $8.75M. The largest seller was Consonance Capital Management, cutting an estimated $15.6M.
- 65 institutional investors held Oxford Immunotec Global PLC Ordinary Shares (OXFD) as of Q1 2020, down from 68 in Q4 2019.
- Funds reported $225M of Oxford Immunotec Global PLC Ordinary Shares stock for Q1 2020, down 44% quarter-over-quarter.
- 5 funds opened new Oxford Immunotec Global PLC Ordinary Shares positions in Q1 2020 and 7 closed out, a net change of -2 holders.
- The largest Oxford Immunotec Global PLC Ordinary Shares buyer in Q1 2020 was Senvest Management, an estimated $8.75M added.
- The largest Oxford Immunotec Global PLC Ordinary Shares seller in Q1 2020 was Consonance Capital Management, an estimated $15.6M sold.
Based on aggregated 13F filings for Q1 2020.